{"summary": "MERS-CoV is an emerging respiratory pathogen with a high mortality rate and no specific treatments available to date. the study was adapted from validated questionnaire originally aimed to measure network capacities and capabilities within the international severe acute and emerging Infection Consortium (ISARIC) the questionnaire was modified for this study to include 26 items that were divided into three main domains of interest. clinical trial of convalescent plasma therapy for MERS-CoV. electronic supplementary material available to authorized users."}